SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commencement of patient dosing in a Phase 1 clinical trial with PEGPH20 in cancer patients with refractory solid tumors. This multi-center, open-label, dose-escalation study will explore the safety, tolerability, pharmacokinetics and radiologic assessment of intravenous administration of PEGPH20 as a single agent with repeat dosing.
